In the EGFR based CAR-T therapy of NSCLC, two patients demonstrated partial response, and five patients displayed stable illness; has demonstrated additional need for CAR-T cells to treat NSCLC in the future. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.